Cocrystal Pharma Inc (COCP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cocrystal Pharma Inc stock (COCP) is currently trading at $1.06. Cocrystal Pharma Inc PS ratio (Price-to-Sales) is 92.45. Analyst consensus price target for COCP is $6.67. WallStSmart rates COCP as Sell.
- COCP PE ratio analysis and historical PE chart
- COCP PS ratio (Price-to-Sales) history and trend
- COCP intrinsic value — DCF, Graham Number, EPV models
- COCP stock price prediction 2025 2026 2027 2028 2029 2030
- COCP fair value vs current price
- COCP insider transactions and insider buying
- Is COCP undervalued or overvalued?
- Cocrystal Pharma Inc financial analysis — revenue, earnings, cash flow
- COCP Piotroski F-Score and Altman Z-Score
- COCP analyst price target and Smart Rating
Cocrystal Pharma Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cocrystal Pharma Inc (COCP) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cocrystal Pharma Inc (COCP) Key Strengths (2)
Trading at 1.87x book value, attractively priced
Strong revenue growth at 26.90% annually
Supporting Valuation Data
Cocrystal Pharma Inc (COCP) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 92.5x annual revenue
Very low institutional interest at 5.59%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Cocrystal Pharma Inc (COCP) Detailed Analysis Report
Overall Assessment
This company scores 24/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (1.87) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 26.90%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (92.45) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -94.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -94.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 26.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
COCP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
COCP's Price-to-Sales ratio of 92.45x trades 45% below its historical average of 168.58x (73th percentile). The current valuation is 95% below its historical high of 1830x set in May 2015, and 40096% above its historical low of 0.23x in Jul 2014. Over the past 12 months, the PS ratio has expanded from ~3.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cocrystal Pharma Inc (COCP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cocrystal Pharma Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 510,000 with 27% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 27% YoY, reaching 510,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 187% of revenue (954,000) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Cocrystal Pharma Inc maintain 27%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cocrystal Pharma Inc.
Bottom Line
Cocrystal Pharma Inc offers an attractive blend of growth (27% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(12 last 3 months)
| Insider | Type | Shares |
|---|---|---|
FROST, PHILLIP MD ET AL Director, 10% Owner | Buy | +20,000 |
| Insider | Type | Shares |
|---|---|---|
FROST, PHILLIP MD ET AL Director, 10% Owner | Buy | +50,000 |
| Insider | Type | Shares |
|---|---|---|
FROST, PHILLIP MD ET AL Director, 10% Owner | Buy | +50,000 |
| Insider | Type | Shares |
|---|---|---|
FROST, PHILLIP MD ET AL Director, 10% Owner | Buy | +20,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:28:24 AM
About Cocrystal Pharma Inc(COCP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic viral diseases. The company is headquartered in Bothell, Washington.